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Carcinoids, originating from cells of the dif-
fuse endocrine system (DES), account for 0.7%
of all malignancies and are characterized by a
slow growth rate and the presence of nonspe-
cific signs and symptoms often making their
detection rather difficult. Gastroente ropancre-
atic neuroendocrine tumors (GEP-NETs) rep-
resent  the  majority  (~70%)  of  DES  tumors.
Historically they account for about 2% of all
gastrointestinal  tumors  but  their  incidence
and prevalence have increased recently, likely
owing to the advances accomplished with new
endoscopy  procedures  and  diagnostic  tools,
and to the achievement of long survival rates
fostered by the indolent evolution of the dis-
ease.  Currently,  according  to  the  algorithm
proposed by Modlin
1for diagnosis and manage-
ment of GEP-NETs normally accepted by clini-
cians  in  routine  clinical  practice,  the  first
action after clinical suspicions of a NET com-
prises the measurement of circulating mark-
ers such as CgA, NSE, serotonin, gastrin, or
urinary  5-hydroxyindoleacetic  acid  (5-HIAA).
In  the  case  of  positive  findings,  the  subse-
quent  action  lies  in  the  octreoscan,  which
allows the topographic localization of the pri-
mary lesion or of metastatic disease. Finally,
the diagnosis is completed through the surgi-
cal resection of the primary tumor or the biop-
sy of the reachable metastases. However, nei-
ther laboratory tests nor octreoscans are com-
pletely reliable diagnostic tools because other
clinical disorders or atypical radiological find-
ings may mimic a carcinoid, hence leading to
an  erroneous  NET  diagnosis.  Consequently,
the distinct possibility of false positive find-
ings exists, being the lack of experience with
the disease the major reason for an incorrect
diagnosis. Indeed, with the exception of some
sporadic case reports,
2 it does not seem that
the matter of the occurrence of false positive
NETs has been taken into consideration sys-
tematically. Based on two years’ experience,
we report the occurrence of eight cases previ-
ously clinically diagnosed as NETs elsewhere,
and then referred to our specialized reference
center  for  pathological  substantiation.  After
investigation,  the  following  diagnoses  were
made:  chronic  atrophic  gastritis  (CAG)  with
enterochromaffin-like  cell  (ECL)  hyperplasia
(4 cases), estrogen-deprivation syndrome (1),
hypochondriac  disorder  (1),  metabolic  syn-
drome (1), and sarcoidosis (1). Relying on this
limited  but  significant  occurrence  rate,  we
deem that some key points should be argued. 
Primarily, a frequent mistake concerns the
interpretation of abnormal CgA plasma values:
this marker, expressed in both functioning and
non functioning NET tumors, shows a thresh-
old of sensitivity and specificity depending on
tumor histology, extension of the disease, and
biological  tumor  activity.
3 Additionally,  the
methods used to measure CgA levels are not
standardized yet, as appears from the compar-
ison of the three commercially available kits,
the outcomes of which may disagree consider-
ably.
4 Other pathological conditions may hin-
der the specificity because CgA elevations can
be detected in some instances in patients with
renal and hepatic failure, untreated hyperten-
sion, inflammatory bowel disease, and even in
the presence of nonendocrine tumors.
5
Lastly,  the  use  of  proton-pump  inhibitors
may be responsible for the elevations of CgA
values, and long-term acid inhibition is a well
known  cause  of  CAG  with  related  ECL  cell
hyperplasia.
6 On  the  basis  of  CgA  values,  it
would  be  best  for  clinicians  to  discriminate
patients  affected  by  carcinoids  from  healthy
subjects and from those whose abnormal find-
ings  depend  on  hyperplastic  lesions  of
endocrine  cells  in  the  context  of  a  CAG.
According  to  our  experience,
7 the  threshold
value of CgA for identifying patients with NETs
should be 36 U/L, which gives a specificity of
83-91%. More recently, however, it has been
highlighted that there is a need to change the
current cutoff CgA values to exclude patients
in whom levels are elevated as a result of non-
neoplastic conditions.
8 The authors set a 95%
specificity,  corresponding  to  cutoff  values  of
84-87  U/L,  arguing  that  this  is  essential  to
exclude  patients  showing  false  positive  CgA
increases  from  unnecessary  examinations
specific for endocrine tumors. In our experi-
ence, when a borderline or doubtful value is
observed, before proceeding to the workup we
repeat the plasma assay with the addition of
the detection of NSE plasma dosage and of uri-
nary  5-HIAA:  the  latter,  particularly,  appears
extremely useful and crucial to this purpose.
9
Another issue critical in making the NET
diagnosis  easier  is  the  correlation  between
marker serum values and referred symptoms
at presentation. It should be highlighted that
at diagnosis the classical carcinoid syndrome
of  flushing,  sweating,  diarrhea,  abdominal
pain,  bronchospasm,  and  right-sided  heart
failure  represents  a  fairly  infrequent  event
occurring in less than 10% of NETs,
10 because
it may depend on the secretion rate of tumor
mediators, tumor size, its anatomical location
and,  chiefly,  the  extent  of  liver  metastases.
Additionally,  octreoscan  findings  should  be
related to the clinical setting always; conse-
quently,  the  need  of  reliable  evidence  is
mandatory.  Notwithstanding  the  fact  that
octreoscan is carried out routinely in hospitals
equipped  with  nuclear  medicine  units,  the
experience of the operators and the adoption
of a correct procedure for the image acquisi-
tion  represent  the  major  issues  to  achieve
reliable results. Based on the largest Italian
experience carried out in three hospitals and
involving 253 patients, a comparison of differ-
ent procedures of octreoscan has demonstrat-
ed  that  the  best  specificity  (88%)  was
obtained when a semiquantitative evaluation
was  employed.
11 In  addition,  this  procedure
showed that bowel preparation is not essen-
tial;  conversely,  when  the  24-hour  image
acquisition  shows  accumulation  in  the
abdomen possibly because of the radioactive
bowel  content,  it  is  extremely  important  to
repeat scintigraphy after 48 hours.
12 The capa-
bility of recognizing all uptake of physiological
tracers and other pathological aspects result-
ing in a false positive octreoscan response can
reduce the false positive results to 3% only.
13 It
should  be  highlighted  that  the  hypophysis,
thyroid,  liver,  spleen,  kidneys,  bladder,  gall-
bladder, and intestinal tract represent areas of
physiological  uptake  of  111In-DTPA-octreo  -
tide,  and  that  somatostatin  receptors  are
found even in activated leukocytes in granulo-
matosis  processes  (sarcoidosis,  tuberculo-
sis)
14 and  chronic  inflammatory  processes
(inflammatory bowel disease, ulcerative coli-
tis, rheumatoid arthritis).
15
In  conclusion,  despite  a  better  general
understanding  of  neuroendocrine  disease  in
terms of natural history, biology, and clinical
behavior, differential diagnosis of NETs should
be extremely extensive and accurate, needing
additional  and  more  definite  investigations.
Awaiting more specific diagnostic tests, clini-
cal  data  and  radiological  findings  should  be
interpreted always by taking the clinical set-
ting, particularly, into consideration. A knowl-
edge of conditions that could mimic a NET is a
key factor in the approach to the disease, and
close cooperation among dedicated physicians,
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pathologists, nuclear medicine specialists, and
conventional  radiologists  is  warranted  to
define  the  optimal  diagnostic  protocol.
Therefore, to save medical resources and to
avoid the patient’s impairment, it is appropri-
ate that those patients strongly suspected of
having a NET should be referred to and man-
aged in highly experienced centers with the
support of a greatly integrated multidiscipli-
nary team.  
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